Advances in emerging drugs for osteosarcoma
CM Hattinger, M Fanelli, E Tavanti, S Vella… - Expert opinion on …, 2015 - Taylor & Francis
Introduction: Osteosarcoma (OS), the most common primary malignant bone tumor, is
currently treated with pre-and postoperative chemotherapy in association with the surgical …
currently treated with pre-and postoperative chemotherapy in association with the surgical …
Emerging drugs for high-grade osteosarcoma
CM Hattinger, M Pasello, S Ferrari, P Picci… - Expert opinion on …, 2010 - Taylor & Francis
Importance of the field: Osteosarcoma (OS) is the most common primary malignant bone
tumour in children and adolescents. This review focuses on the most promising therapeutic …
tumour in children and adolescents. This review focuses on the most promising therapeutic …
State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma
C Meazza, SD Asaftei - Expert Opinion on Pharmacotherapy, 2021 - Taylor & Francis
Introduction: Advances in the treatment of osteosarcoma (OS) came in the mid-1970s, when
adding chemotherapy to surgery significantly improved patient survival. OS outcomes have …
adding chemotherapy to surgery significantly improved patient survival. OS outcomes have …
An update on emerging drugs in osteosarcoma: towards tailored therapies?
CM Hattinger, MP Patrizio, F Magagnoli… - Expert opinion on …, 2019 - Taylor & Francis
Introduction: Current treatment of conventional and non-conventional high-grade
osteosarcoma (HGOS) is based on the surgical removal of primary tumor and, when …
osteosarcoma (HGOS) is based on the surgical removal of primary tumor and, when …
New targets and approaches in osteosarcoma
J Gill, MK Ahluwalia, D Geller, R Gorlick - Pharmacology & therapeutics, 2013 - Elsevier
Osteosarcoma is the most common primary tumor of bone. Approximately 2/3 of patients
who present with localized osteosarcoma can be expected to be cured of their disease with …
who present with localized osteosarcoma can be expected to be cured of their disease with …
Recent advances in osteosarcoma
SM Botter, D Neri, B Fuchs - Current opinion in pharmacology, 2014 - Elsevier
Highlights•Although rare, bone cancers frequently cause death in the pediatric population.•
Osteosarcoma patient survival has plateaued over the last 20 years.•The large tumor …
Osteosarcoma patient survival has plateaued over the last 20 years.•The large tumor …
An update on chemotherapy for osteosarcoma
S Ferrari, M Serra - Expert opinion on pharmacotherapy, 2015 - Taylor & Francis
Introduction: In the early seventies chemotherapy significantly improved survival in
osteosarcoma. Since then minor innovations have occurred although recent years have …
osteosarcoma. Since then minor innovations have occurred although recent years have …
Osteosarcoma: current treatment and a collaborative pathway to success
MS Isakoff, SS Bielack, P Meltzer… - Journal of clinical …, 2015 - ascopubs.org
Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and
young adults. Before 1970, treatment primarily included surgical resection. However, the …
young adults. Before 1970, treatment primarily included surgical resection. However, the …
Osteosarcoma: accelerating progress makes for a hopeful future
AJ Saraf, JM Fenger, RD Roberts - Frontiers in oncology, 2018 - frontiersin.org
Patients who develop osteosarcoma in 2017 receive treatment that remains essentially
unchanged since the 1970s. Outcomes likewise remain largely unimproved. Large …
unchanged since the 1970s. Outcomes likewise remain largely unimproved. Large …
Chemotherapy for osteosarcoma–Where does it come from? What is it? Where is it going?
N Yamamoto, H Tsuchiya - Expert opinion on pharmacotherapy, 2013 - Taylor & Francis
Introduction: Although chemotherapy is currently indispensable for the treatment of
osteosarcoma, chemotherapy for this rare cancer has not been developed based on …
osteosarcoma, chemotherapy for this rare cancer has not been developed based on …